CN101821269B - 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 - Google Patents

2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 Download PDF

Info

Publication number
CN101821269B
CN101821269B CN200880111585.7A CN200880111585A CN101821269B CN 101821269 B CN101821269 B CN 101821269B CN 200880111585 A CN200880111585 A CN 200880111585A CN 101821269 B CN101821269 B CN 101821269B
Authority
CN
China
Prior art keywords
benzimidazole
methylpyrrolidin
abt
carboxamide
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880111585.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101821269A (zh
Inventor
G·朱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories, AbbVie Inc filed Critical Abbott Laboratories
Publication of CN101821269A publication Critical patent/CN101821269A/zh
Application granted granted Critical
Publication of CN101821269B publication Critical patent/CN101821269B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880111585.7A 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2 Expired - Fee Related CN101821269B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97965407P 2007-10-12 2007-10-12
US60/979,654 2007-10-12
PCT/US2008/079439 WO2009049109A1 (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410190297.2A Division CN104230893A (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Publications (2)

Publication Number Publication Date
CN101821269A CN101821269A (zh) 2010-09-01
CN101821269B true CN101821269B (zh) 2014-05-28

Family

ID=40279000

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880111585.7A Expired - Fee Related CN101821269B (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
CN201410190297.2A Pending CN104230893A (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410190297.2A Pending CN104230893A (zh) 2007-10-12 2008-10-10 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Country Status (8)

Country Link
US (1) US8013168B2 (enExample)
EP (2) EP2727921B1 (enExample)
JP (3) JP2011500588A (enExample)
CN (2) CN101821269B (enExample)
CA (1) CA2696423A1 (enExample)
ES (1) ES2562081T3 (enExample)
MX (1) MX2010003771A (enExample)
WO (1) WO2009049109A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100090769A (ko) * 2007-10-12 2010-08-17 아보트 러보러터리즈 2-((ｒ)-2-메틸피롤리딘-2-일)-1ｈ-벤즈이미다졸-4-카복스아미드 결정형 1
AU2012243132A1 (en) * 2011-04-11 2013-10-24 Abbvie Inc. PARP inhibitors for the treatment of CIPN
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
US20190092756A1 (en) * 2016-03-09 2019-03-28 Crystal Pharmatech Co., Ltd. Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184208C (zh) * 1998-11-27 2005-01-12 巴斯福股份公司 取代的苯并咪唑及其制备和用途
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
CN1926127A (zh) * 2003-12-29 2007-03-07 万有制药株式会社 新的2－杂芳基取代苯并咪唑衍生物
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
KR20100090769A (ko) 2007-10-12 2010-08-17 아보트 러보러터리즈 2-((ｒ)-2-메틸피롤리딘-2-일)-1ｈ-벤즈이미다졸-4-카복스아미드 결정형 1

Also Published As

Publication number Publication date
CN104230893A (zh) 2014-12-24
JP2014237660A (ja) 2014-12-18
JP2017071617A (ja) 2017-04-13
EP2217603A1 (en) 2010-08-18
WO2009049109A1 (en) 2009-04-16
CN101821269A (zh) 2010-09-01
US8013168B2 (en) 2011-09-06
US20090099246A1 (en) 2009-04-16
JP2011500588A (ja) 2011-01-06
EP2727921A1 (en) 2014-05-07
EP2727921B1 (en) 2017-04-19
CA2696423A1 (en) 2009-04-16
EP2217603B1 (en) 2015-11-18
ES2562081T3 (es) 2016-03-02
MX2010003771A (es) 2010-04-21

Similar Documents

Publication Publication Date Title
US9580410B2 (en) 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1
CN101821269B (zh) 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
CN101827824B (zh) 结晶化学治疗剂
CN101827821B (zh) 结晶化学治疗剂
JP2011500708A (ja) 結晶性化学療法薬
CN101827822B (zh) 结晶的吲唑衍生的化学治疗剂
US8759538B1 (en) Crystalline chemotherapeutic
HK1197642B (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBOTT HOSPITAL CO., LTD.

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20131213

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Bahamas Nassau

Applicant after: AbbVie Inc.

Address before: Bahamas Nassau

Applicant before: Abbott Laboratories Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ABBOTT HOSPITAL CO., LTD. TO: ABBVIE BAHAMAS B.V.

TA01 Transfer of patent application right

Effective date of registration: 20131213

Address after: Bahamas Nassau

Applicant after: Abbott Laboratories Ltd.

Address before: Illinois State

Applicant before: ABBOTT LABORATORIES

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20161011

Address after: Bermuda Hamilton

Patentee after: AbbVie Inc.

Address before: Bahamas Nassau

Patentee before: AbbVie Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140528

Termination date: 20181010